1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Gestational Diabetes Global Clinical Trials Review, H1, 2016

Gestational Diabetes Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Gestational Diabetes Global Clinical Trials Review, H1, 2016" provides an overview of Gestational Diabetes clinical trials scenario. This report provides top line data relating to the clinical trials on Gestational Diabetes. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Gestational Diabetes Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Gestational Diabetes Therapeutics Clinical Trials 27
Prominent Drugs 29
Clinical Trial Profile Snapshots 30
Appendix 105
Abbreviations 105
Definitions 105
Research Methodology 106
Secondary Research 106
About GlobalData 107
Contact Us 107
Disclaimer 107
Source 108

List of Tables
Gestational Diabetes Therapeutics, Global, Clinical Trials by Region, 2016* 6
Gestational Diabetes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Gestational Diabetes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Gestational Diabetes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Gestational Diabetes Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Gestational Diabetes Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Gestational Diabetes Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Gestational Diabetes Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
Gestational Diabetes Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Gestational Diabetes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
Gestational Diabetes Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Gestational Diabetes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Gestational Diabetes Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Gestational Diabetes Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Gestational Diabetes Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Gestational Diabetes Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Gestational Diabetes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Gestational Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Gestational Diabetes Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Gestational Diabetes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 28
Gestational Diabetes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29

List of Figures
Gestational Diabetes Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Gestational Diabetes Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Gestational Diabetes Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Gestational Diabetes Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Gestational Diabetes Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Gestational Diabetes Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Gestational Diabetes Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Gestational Diabetes Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials, G7 Countries (%), 2016* 14
Gestational Diabetes Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Gestational Diabetes Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Gestational Diabetes to Metabolic Disorders Clinical Trials, E7 Countries (%), 2016* 17
Gestational Diabetes Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Gestational Diabetes Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Gestational Diabetes Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Gestational Diabetes Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Gestational Diabetes Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Gestational Diabetes Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Gestational Diabetes Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Gestational Diabetes Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Gestational Diabetes Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Gestational Diabetes Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Gestational Diabetes Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 29
GlobalData Methodology 106

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Type 2 Diabetes Mellitus - GPCRs and Protein Kinases Dominate Pipeline, with Most Promising First-in-Class Targets Demonstrating Potential Disease-Modifying Effects Summary Type 2 diabetes ...

Diabetes Injection Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2016 - 2024

Diabetes Injection Pens Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • December 2016
  • by Transparency Market Research

Global Diabetes Injection Pens Market: Overview This report on diabetes injection pens market studies the current as well as future prospects of the market globally. The stakeholders of this report include ...

Global Diabetes Diagnostics Industry

Global Diabetes Diagnostics Industry

  • $ 4950
  • Industry report
  • October 2016
  • by Global Industry Analysts

This report analyzes the worldwide markets for Diabetes Diagnostics in US$ Thousand by the following Product Segments: Continuous Glucose Monitoring (CGM) Systems, HbA1c Testing Devices, and Blood Glucose ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.